All In Biotech

Investigational drug · Phase 2

LSALT Peptide

Also called: Metablok

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Kidney Injury, Cardiac Surgery.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

4

Any phase or sponsor naming "LSALT Peptide"

First trial start

2024

Mar 8, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LSALT Peptide", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acute Kidney Injury
  • Cardiac Surgery

Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "LSALT Peptide" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Acute Kidney Injury

  • QRX-3EseronatePhase 32 trials

    Ebima Clifford Okundaye · Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure

  • R2R01Phase 22 trials

    River 2 Renal Corp. · Acute Kidney Injury, Hepatorenal Syndrome

  • AZD4144Phase 21 trial

    AstraZeneca · Sepsis, Acute Kidney Injury

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.